Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.
Advertisement

Related Content

Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
Roche Gears Up To Launch Actemra; Lines Up More Clinical Research In India
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Japanese Regulators Enforcing More Post-Market Surveillance: Wyeth’s Observations From Enbrel’s Three-year Zenrei Chosa (Part 2 of 2)
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
Advertisement
UsernamePublicRestriction

Register

SC071128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel